文献速递系统性红斑狼疮

mTOR信号通路在系统性红斑狼疮发病机制中的研究进展

Advances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway.
PubMed 文献 · Semin Arthritis Rheum · 2019-11-11

该综述检索了截至2019年4月的多个数据库,纳入69篇文献,总结mTOR信号通路与免疫细胞增殖分化、炎症因子分泌、自噬异常及氧化应激相关,参与SLE发病;mTOR抑制剂在SLE临床试验中的疗效与安全性已获初步确认,但需更大样本试验验证。

要点

  • mTOR信号通路参与SLE发病,与免疫细胞异常、炎症因子分泌等相关
  • mTOR抑制剂在SLE临床试验中的疗效与安全性已获初步确认
  • 仍需更大规模临床试验确定mTOR靶向治疗的疗效与耐受性

核心结论

  • mTOR信号通路与SLE发病机制密切相关。
  • mTOR抑制剂在SLE临床试验中的疗效与安全性已获初步确认。
  • 需更多更大规模临床试验确定mTOR靶向治疗在SLE精准医学中的价值。

研究设计与样本

  • 检索PubMed、OVID、Embase、Web of Science和Cochrane图书馆数据库至2019年4月。
  • 以「systemic lupus erythematosus」「mammalian target of rapamycin (mTOR)」「signaling pathway」组合关键词检索。
  • 共检索到329篇文章,最终纳入69篇进行综述。
  • 因研究设计异质性,适当采用不同质量评估工具。

主要发现

  • mTOR信号通路与免疫细胞增殖分化、炎症细胞因子分泌、自噬异常及氧化应激密切相关。
  • mTOR信号通路在SLE发病机制中发挥重要作用。
  • mTOR抑制剂在SLE临床试验中的疗效与安全性已获初步确认。

临床怎么用

  • mTOR信号通路可作为SLE精准医学治疗的潜在新靶点。
  • mTOR抑制剂在SLE中的应用需更多临床试验验证疗效与耐受性。

局限性

  • 研究设计存在异质性,采用不同质量评估工具。
  • 需更广泛和更大样本量的未来研究确定mTOR抑制剂的疗效与耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To elucidate the role of mTOR signaling pathway in the pathogenesis of systemic lupus erythematosus (SLE) and possible applications of the inhibitors in treatment of SLE. METHODS: PubMed, OVID, Embase, Web of Science, and Cochrane library databases were searched up to April 2019 with combined keywords of 'systemic lupus erythematosus', 'mammalian target of rapamycin (mTOR)' and 'signaling pathway'. Studies reporting mTOR and pathogenesis of SLE were included. Given the heterogeneity in study design, different quality assessment tools were applied appropriately. RESULTS: We retrieved 329 articles, among which 69 were included in the review. The available evidences have shown that mTOR signaling pathway is closely associated with the proliferation and differentiation of immune cells, the secretion of inflammatory cytokines, the abnormalities of autophagy and oxidative stress, and plays an important role in the pathogenesis of SLE. The efficacy and safety of mTOR inhibitors in SLE clinical trials have been initially confirmed. CONCLUSIONS: mTOR signaling pathway is closely related to the pathogenesis of SLE. The improved understanding of immunoregulation and the completion of more clinical trials is expected to define mTOR-targeted therapeutic intervention as a new target for precision medicine of treatment of SLE. More extensive and future research with larger trial populations is required to determine its efficacy and tolerability.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. He J, Ma J, Ren B, et al. Advances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway. Semin Arthritis Rheum. 2019. PMID: 31796213. doi:10.1016/j.semarthrit.2019.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。